Acquisition Expands Medical Device Clinical Research Capabilities and Expertise.
Today, it is with delight that I announce that NAMSA has acquired New York-based Clinical Research Organization (CRO), Syntactx. Founded in 2010, Syntactx has a rich history and proven track record of synthesizing clinical evidence for global medtech Sponsors to enable broad market adoption and commercial success of innovative medical products through their deep-rooted understanding of enrollment obstacles and regulatory challenges and obligations.
Most notably, this new partnership will enhance NAMSA’s already robust cardiovascular-focused regulatory consulting and clinical research solutions, while expanding Electronic Data Capture (EDC), core lab imaging, safety, and physician consulting service offerings. These areas are key to further strengthening NAMSA’s rich history of assisting Sponsors to proactively tackle development challenges head-on, achieve commercialization success and positively impact patient lives.
While this is an exciting change for all of us at NAMSA and for Clients, our focus remains on providing you with the exceptional service you have come to expect from our experts and project teams. In an effort to ensure continuity of service, clear communication and continued exceptional outcomes of ongoing projects, please continue to communicate with your current day-to-day NAMSA contacts for ongoing and future projects.
To learn more about today’s announcement, we invite you to access NAMSA’s Press Release, here. You may also reach out to your Sales Representative with questions.
Thank you again for your dedication to improving patient lives and healthcare outcomes across the world.
Sincerely,
John Gorski
NAMSA President and CEO
